The anti-HCV RIBA test verifies the presence of anti-HCV serum antibodies detected by the Elisa test. In Côte d'Ivoire, screening for hepatitis C is done exclusively by enzyme immunoassays. In order to reduce the number of HCV positive blood donor exclusions on ELISA, we conducted this study which aimed to demonstrate the value of the RIBA test in confirming diagnosis of viral hepatitis C to blood donors.
Our study, which took place from 02 to 23 February 2008 in the laboratory of Abidjan NBTC, focused on 200 sera of blood donors anti-HCV positive (Elisa test) selected according to the ratio. The DECISCAN HCV PLUS confirmation test of BIORAD was used.
Among the 200 HCV samples positive by EIA, 49% (98/200) were confirmed positive. RIBA gave an indeterminate result in 40% of cases (80/200); and negative in 11% of cases (22/200) corresponding to false ELISA devices. In RIBA 96 samples had a low ELISA ratio of which 21% (20/96) were RIBA negative, and 79% (76/96) were indeterminate. RIBA positive samples (98/200) had a high ratio in 82% of cases (80/98). The presence of NS3 (C33) and NS4 (C100) was noted in 100% of cases (98/98, C2 in 37% (36/98) of cases and C1 in 18% of cases (18/98). RIBA indeterminate noted the presence of NS3 in 98% of cases (78/80) and NS4 in 30% of cases (24/80). Proteins C1, C2 and NS4 are essential for the diagnosis of confirmation of viral hepatitis C by RIBA.
These results attest to the lower specificity of enzyme immunoassays (ELISAs); hence the benefit of using RIBA confirmatory tests. A significant number of donors are excluded from blood donation in Côte d'Ivoire on the basis of false positive results obtained by the ELISA technique.
Academic Editor: Godwin Ajayi, Prenatal Diagnosis and Therapy Centre, College of Medicine Univ. of Lagos, Lagos/Nigreiagos.
Checked for plagiarism: Yes
Review by: Single-blind
Copyright © 2019 I.I. Nefyodov, et al.
The authors have declared that no competing interests exist.
The transfusion of blood and its derivatives is essential for the treatment of various medical and surgical pathologies. However, it has certain undesirable effects, including immunological and infectious complications 1.
The role of transfusion in HIV transmission was demonstrated in the 1980s and led to the introduction of the transfusion safety concept for infectious agents.
Rigorous medical screening combined with systematic screening for the main infectious markers (HIV, Hepatitis B, Hepatitis C, syphilis) contributes to a reduction in the risk of transmission 1.
Viral hepatitis C is a public health problem. According to the World Health Organization (WHO), an estimated of 200 million people are infected with this virus, or about 3% of the world's population 2. The developing countries of Southeast Asia and Sub-Saharan Africa are highly endemic areas with rates above 2.5%, while developed countries are areas of low endemicity with rates between 0 and 2.5% 2, 3, 4. The various activity reports of the National Blood Transfusion Center of Côte d’Ivoire reported a prevalence of 4.2% among blood donors 5, 6.
Enzyme immunoassays are the most used in blood transfusion and are described as very sensitive, and unspecific generating false positives 7 which result in the reduction of the number of donors. It is recommended to use a specific confirmatory test including Recombinant Immunoblot Assay (RIBA) 8, 9. RIBA is also an alternative to very expensive PCR for resource-limited countries.
The estimation of HCV seroprevalence among Côte d'Ivoire blood donors estimated (4.2%) based on the results of ELISA could be overestimated, due to false positives that they generate. It therefore seemed appropriate to carry out this study whose objective was to demonstrate the interest of the RIBA test in the confirmation diagnosis of viral hepatitis C to Cote d'Ivoire blood donors
This is a cross-sectional prospective study that was conducted from February 2008 to August 2008 at the National Blood Transfusion Center (CNTS) laboratory located at Kilometer 4 Boulevard de Marseille, Treichville in Abidjan.
Our study focused on a panel of 200 positive anti-HCV ELISA samples from the CNTS serum bank.
HCV testing was performed with Abbott's Murex anti-HCV reagent (version 4.0) based on the enzyme-linked immunoassay (ELISA) technique.
In order to confirm the positive screening results we used BIORAD's DECISCAN HCV PLUS test. It is an online test that uses as a solid support, a membrane fixed on a plastic strip, where are successively coated (i) a control: Anti-human IgG, (ii) a fusion protein Glutathione S Transferase (GST) fused to the genes coding for the NS3 and NS4 proteins used as control (iii) HCV antigens of the nonstructural region: NS3 and NS4 and peptides of the C1 and C2 structural region.
All samples were thawed and homogenized prior to testing as recommended by the manufacturer.
The interpretation criteria are detailed in Table 1.
The donors from whom the indeterminate samples were obtained were serologically monitored at 3 months and 6 months. This follow-up consisted of the detection of anti-HCV antibodies by ELISA technique.
The Epi Info 6.04 software was used for data entry and statistical analysis.Table 1. Criteria for interpreting the results.
|No HCV antigen band displayed||NEGATIF|
|1 HCV antigen band visualized or 2 HCV antigen bands visualized on the capsid gene (C1, C2)||INDETERMINE|
|2 visualized HCV antigen bands from 2 different genes (capsid gene, NS3 gene, NS4 gene) and with an intensity of 0.5+||POSITIVE PROBABLE|
|At least 2 visualized HCV antigen bands from 2 different genes (capsid gene, NS3 gene, NS4 gene) and with an intensity greater than 0.5+||POSITIVE|
Prevalence of Anti HCV Positive Antibodies by Desiscan hcv plus BIORAD (Table 2)
Of the 200 samples tested, 98 were RIBA positive or 49% positive.
The analysis of the results of RIBA according to the ratios (OD / VS) obtained at the ELISA is summarized in Table 2. Samples with a ratio between 8.01 and 16 were all positive.Table 2. Anti HCV Ab positivity rate with DESISCAN HCV plus BIORAD as a function of the ELISA ratio.
|RATIO = DO/VS||Nomber (%) RIBA|
|1,01 – 5 (n=96)||20 (20.8)||76 (79.2)||0 (0)|
|5,01 – 8 (n=24)||2 (8.3)||4 (16.7)||18 (75)|
|8,01 – 16(n=80||0 (0)||0 (0)||80 (100)|
|TOTAL (n=200)||22 (11.0)||80 (40)||98 (49)|
Listed Proteins and RIBA Results (Table 3)
The proteins found in RIBA according to the different results are listed in Table 3. We observed a reactivity of all the proteins tested when the RIBA was positive.Table 3. Proteins listed and RIBA results
RIBA-Positive HCV Ab Relationship and Donor Status (Table 4)
Of the HCV positive RIBA samples, those from new donors accounted for 59%. The RIBA positivity rate was not statistically different for both types of donors (Table 4)Table 4. RIBA positivity and status of the donor
|Donor status||Frequency||Percentage (%)|
Prevalence of HCV Ab Ab after Control of Undetermined RIBA Specimens by ELISA (Table 5)
Only 40 of the 80 donors followed for an indeterminate RIBA result returned.
The positivity rate of the anti-HCV antibodies after the control performed in these undetermined RIBA donors was 50% (Table 5).Table 5. Prevalence of anti HCV Ab after control of RIBA samples indetermined by the Elisa technique
|Antibody anti- VHC||Frequency||Percentage (%)|
The detection of antibodies against HCV is a systematic analysis performed during the biological qualification of blood donations in Côte d'Ivoire. This contributes to strengthening blood safety. However, the majority of enzyme immunoassays are responsible for a false positive with a high rate of rejection of blood products but also a postponement of donors 10.
The use of more specific confirmation tests is necessary. We therefore evaluated the interest of the DECISCAN HCV PLUS BIORAD immunoblot test on 200 ELISA-positive HCV sera.
We observed a RIBA positivity rate of 49%. This result is consistent with that of Mets et al 11 who found 48% in Rwanda. On the other hand, this rate contrasts with that of Maniez-Montreuil and Dubois 11 who found that only 17.6% of the positive signals observed with the enzyme immunoassays (EIA) were confirmed positive. This could be explained by the fact that African countries are areas of high endemicity 12.
RIBA gave an indeterminate result in 40% of cases. This rate is much higher than the 24.7% of indeterminate results reported by Maniez-Montreuil and Dubois 11.
In our study, we observed 11% negative RIBA. In this case, these are false positives observed with the EIA screening tests. This false positive rate is lower than the 57.7% obtained by Maniez-Montreuil and Dubois 12. The proportion of negatives can be partly explained by the high sensitivity of the EIA screening tests on the one hand and the fact that the antibodies detected are residual despite the elimination of the virus by the immune system 13 .
Analysis of the RIBA results by ELISA ratio showed that 79.2% of the samples with a ratio between 1.01 and 5 were indeterminate. Our results are close to 73.7% reported by Pereira et al. 14 in Brazil.
On the other hand our results are superior to those of Othinger et al 7 who found 18% of indeterminate cases for ratios <5. The difference could be explained by the fact that their screening was carried out by chemiluminescence which seems more specific than the ELISA 15
All positive samples had a ratio between 8.01 and 16. This result is in agreement with the findings of Othinger et al 7 who showed that the majority of RIBA positive samples had a high ratio.
Among the positive samples, the presence of NS3 (C33) and NS4 (C100) was noted in 100% of cases. C2 was present in 36.6% of cases and C1 in 18.3% of cases.
These results are superimposable to those reported in other studies including that of Othinger et al 7 and Powlotsky et al. 9 found a reactivity of 84.54% and 96%, and 85% respectively at NS4, NS3, C1 and C2.
Among the indeterminate RIBAs, NS3 was found in 97.22% of cases. Our observations are similar to those of Pereira et al (Pereira et al., 2014), which report a reactivity rate of 86%). On the other hand, 50% of the indeterminate RIBA controlled cases gave a positive result by ELISA and 35% were negative. Thus, NS3 and NS4 detected with the undetermined RIBA, are sensitive but not specific because other viruses can possess them. C1 and C2 are very specific. NS4 is more specific than NS3. Therefore C1, C2 and NS4 proteins are essential for the diagnosis of confirmation of viral hepatitis C by RIBA.
No protein was found when RIBA is negative. This result agrees with that of Margret Othinger et al 7 who also did not demonstrate the presence of proteins.
New donors represent the highest proportion of HCV positive RIBA samples in our study. In fact, 59% of HCV positive for RIBA are new donors. This result is consistent with that of the 1998 study by Mets et al. 11 which showed that the majority of positives are found among new donors. This can be explained by the fact that over time the false positives are removed from the donation of blood.
This study shows that 51% of the ELISA-reactive samples are false positives.
It has shown that an ELISA ratio higher than 8 can be considered to define the true positives with the EIA technique.
RIBA is of particular interest in the confirmation of ELISA positive HCV serologies, in particular for a blood transfusion service when the ratios are less than 8.
It would therefore be desirable to include the RIBA test in the Hepatitis C screening algorithm at the biological qualification laboratory for blood donation in Côte d'Ivoire.
- 1. (1993) Courouce Anne-Marie Progrès du dépistage des porteurs du virus chez les donneurs de sang: risques résiduels (hépatites et rétrovirus). , Gaz. Transfus 89(90), 96-99.
- 2.Organisation Mondiale de la Santé (OMS): Principaux repères sur l’hépatite C. Disponiblehttps://www.who.int/fr/news-room/factsheets/detail/hepatitis-c.
- 3.Renard F, Autier M, Domont D. (2005) L'hépatite C en Belgique, comment améliorer le dépistage et la prévention? UCL- RESO, Un.Educ.Santé. 05-34.
- 4.J P Galmiche, Aubrege A, Assie P, AL. (1997) Conférence de consensus, hépatite C : dépistage et traitement: 16-17 janvier. , Paris, France
- 7.Oethinger Margret, Donald R Mayo, JO Anne Falcone, Pankaj K, Banna.Efficiency of the ontho Vitros Assay for detection of hepatitis C virus- specific anti bodies increased by elimination of supplemental testing of samples with very low sample-to-cutoff ratios. , Journal of clinical Microbiology,May2005 2477-2480.
- 8.Dubois F, Barin F, Goudeau A. (1998) Sérologie anti-VHC pour le dépistage, le diagnostic et la surveillance de l'hépatite C: place de l'immunoblot. Ann Biol Clin. 6, 417-26.
- 9.J M Pawlotsky, Bastie A, Pellet C, Remire J, Darthuy F et al. (1996) Significance of indeterminate third-generation hepatitis C virus recombinant immunoblot assay. , J.Qin.Microbiol 34, 80-83.
- 10.Marta Bes, Juan Ignacio Esteban, Casamitjana N, Piron Maria, Quer Josep et al. (2009) Hepatitis C Virus (HCV)-Specific T-Cell Responses among Recombinant Immunoblot Assay-3-Indeterminate Blood Donors: A Confirmatory Evidence of HCV Exposure. , Transfusion 49(7), 1296-1305.
- 11.Mets T, Smitz J, Ngend A, Haya P, Sabbe L et al. (1995) Hepatitis C virus infection in African patient with chronic hepatitis cirrhosis and hepatocellular carcinoma: a comparative study in Niger. Ann J trop Hyg. 52, 293-6.
- 12.MontreuiL M-Maniez-. (2000) F Dubois Interpretation de l’hépatite C : immunoblot et amplication générique tra,sfus clim Biol ;. 7(1), 25-30.
- 13.Rotily R, Loubriere S, Nixon J, Bourliere M, Halfan P et al. (1997) Sensibilité, spécificité et coûts des tests dépistage de l'infection par le VHC utilisés dans l'analyse de décision. , Gastroenterol Clin Biol 20, 33-40.
- 14.Felicidade Mota Pereira. (2014) Maria Alice Sant’ana Zarife, Eliana Almeida Gomes Reis, Mitermayer G. Reis. Indeterminate RIBA Results Were Associated with the Absence of Hepatitis C Virus RNA (HCV-RNA) in Blood Donors ». Revista Da Sociedade Brasileira de Medicina Tropical 47(1), 1217.
Cited by (1)
- 1.OCAL Murat, BULUT Mehmet Emin, 2022, Determination of anti-HCV signal to cut-off value in patients with hepatitis C virus infection and the variety of antibody responses, The European Research Journal, (), 1, 10.18621/eurj.945588